HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Kozo Ishino Shunji Sano Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sangawa, K. Articles by Sano, S. Search for Related Content PubMed PubMed Citation Articles by Sangawa, K. Articles by Sano, S. Related Collections Myocardial protection

Ann Thorac Surg 2004;77:233-237
© 2004 The Society of Thoracic Surgeons

---

Original article: cardiovascular

Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart

^a Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan

Accepted for publication July 30, 2003.

^* Address reprint requests to Dr Ishino, Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama-City 700-8558, Japan
e-mail: ishino{at}tb3.so-net.ne.jp

BACKGROUND: Atrial natriuretic peptide (ANP), a stimulator of particulate guanylate cyclase, has been found to protect against reoxygenation-induced hypercontracture in isolated cardiomyocytes by increasing cyclic guanosine monophosphate synthesis. The purpose of this study was to investigate the cardioprotective effects of ANP against ischemia-reperfusion injury in isolated rat hearts.

METHODS: Twenty-four hearts were perfused with ANP at 0.01, 0.1, and 1 µmol/L or without ANP (n = 6 each) in normoxic conditions. Because 0.1 µmol/L ANP induced a threefold increase in cyclic guanosine monophosphate release into the coronary effluent without any effect on cardiac function, we used the 0.1 µmol/L ANP dose for ischemia-reperfusion studies. Eighteen hearts were subjected to 15 minutes of normothermic global ischemia followed by 15 minutes of reperfusion. The hearts were divided into three groups (n = 6 each). In group 1, ANP was added before ischemia. In group 2, ANP was added to the reperfusate. Hearts were untreated in the control group.

RESULTS: In group 1, the postischemic recovery of cardiac output, coronary flow, and cyclic guanosine monophosphate release was similar to the control group. In group 2, the recovery of cardiac output was significantly better than the control group (82.1% ± 9.8% vs 61.8% ± 6.8%, respectively, p < 0.01) with a similar trend to recovery of coronary flow (90.7% ± 8.5% vs 79.3% ± 11.8%, respectively). The improved cardiac function was closely related to a significant increase in postischemic cyclic guanosine monophosphate release.

CONCLUSIONS: Administration of ANP at the time of reperfusion protects the myocardium from ischemia-reperfusion injury. The concentrations of administration must not only increase the release of cyclic guanosine monophosphate release, but also lack negative inotropic effects.

This article has been cited by other articles:

				S. Kasama, M. Furuya, T. Toyama, S. Ichikawa, and M. Kurabayashi Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction Eur. Heart J., June 2, 2008; 29(12): 1485 - 1494. [Abstract] [Full Text] [PDF]

				W. W. Zhang, N. W. Hasaniya, S. Premaratne, and J. J. McNamara Atrial Natriuretic Peptide Protects Against Ischemia-Reperfusion Injury in Rabbit Hearts In Vivo Vascular and Endovascular Surgery, June 1, 2008; 42(3): 263 - 267. [Abstract] [PDF]

				T. Nishikimi, N. Maeda, and H. Matsuoka The role of natriuretic peptides in cardioprotection Cardiovasc Res, February 1, 2006; 69(2): 318 - 328. [Abstract] [Full Text] [PDF]